Botulinum toxin (OnabotulinumtoxinA) in the male non‐neurogenic overactive bladder: clinical and quality of life outcomes

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|S3|61-65

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.S3, 2015-10, pp. : 61-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Botulinum toxin: historical perspective and treatment of neurogenic and idiopathic overactive bladder

By Mulligan Daniel   Bologna Raymond  

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 165-175

Future Medicine

Access to resources Recommend Favorite

Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 675-678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 2, 2015-01 ,pp. : 128-134

Bentham Science Publishers

Access to resources Recommend Favorite

Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis

By  

Urologia Internationalis, Vol. 91, Iss. 4, 2013-08 ,pp. : 429-438

Karger

Access to resources Recommend Favorite

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

By Mallett Veronica   Burks David   Garely Alan D.   Smith Neila  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 821-831

Informa Healthcare

Access to resources Recommend Favorite